Abstract

To the Editor:

Murphy et al¹ recently published an analysis of the factors influencing the rapid review (RR) outcome in Ireland. The RR process is a pivotal part of the drug appraisal and reimbursement process, and analysis of factors associated with its outcomes is an important research question. RR outcomes may affect the speed of access of new drugs to patients. As members of the National Centre for Pharmacoeconomics (NCPE) Review Group who conduct the evaluations, we wanted to take the opportunity to provide further insight into the process and discuss the article’s findings.